Page 6 - Otonomy Inc News Today

Analysts expect Otonomy, Inc. (NASDAQ:OTIC – Get Rating) to announce earnings per share (EPS) of ($0.19) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Otonomy’s earnings, with estimates ranging from ($0.23) to ($0.17). Otonomy posted earnings of ($0.23) per share in the same quarter last year, which would suggest a […]

Squarepoint Ops LLC decreased its holdings in Otonomy, Inc. (NASDAQ:OTIC – Get Rating) by 56.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,230 shares of the biopharmaceutical company’s stock after selling 33,456 shares during the period. Squarepoint Ops LLC’s holdings […]

15.03.2022 - SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) - Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 ...

Zacks Investment Research downgraded shares of Otonomy (NASDAQ:OTIC – Get Rating) from a buy rating to a hold rating in a report released on Friday morning, Zacks.com reports. According to Zacks, “Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner […]

10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM ... | March 7, 2022

OTIC earnings call for the period ending December 31, 2021.

Cisplatin-Induced Hearing Loss (CIHL) – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Cisplatin-Induced Hearing Loss (CIHL) – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

03.01.2022 - SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) - Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright BioConnect ...

Robinson’s expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management team...